Trials / Completed
CompletedNCT00239356
Aripiprazole for Schizophrenia Outpatients Completing BMS Clinical Trials
Aripiprazole (BMS-337039) for Outpatients With Schizophrenia Completing Aripiprazole Clinical Trials: A Non-Comparative Rollover Protocol
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 119 (actual)
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc. · Industry
- Sex
- All
- Age
- 18 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to provide aripiprazole to schizophrenic outpatients and Community Treated Patients who are currently receiving aripiprazole therapy on another BMS sponsored clinical trial.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Aripiprazole | Tablets, Oral, 10 - 30 mg, once daily, greater than 52 weeks depending upon Aripiprazole approval in respective country |
Timeline
- Start date
- 2003-03-01
- Primary completion
- 2012-10-01
- Completion
- 2012-10-01
- First posted
- 2005-10-17
- Last updated
- 2014-12-19
- Results posted
- 2014-01-10
Locations
20 sites across 11 countries: Canada, Croatia, Czechia, France, Hungary, Netherlands, Poland, Romania, Russia, South Africa, United Kingdom
Source: ClinicalTrials.gov record NCT00239356. Inclusion in this directory is not an endorsement.